Feature

Special Article

Diabetes Clinical Pathways: Going Beyond Treatment Decisions

12/09/2016

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Diabetes guidelines increasingly go beyond treatment recommendations to take into account quality measures for diabetes care that exist within new value-based systems, addressing the roles and responsibilities of...

...

12/09/2016

Journal of Clinical Pathways

From the Field

A Novel Case Management System to Address Patient-Identified Concerns in Hematology and Oncology Clinical Pathways

10/12/2016

Joleen Hubbard , MD;

Angelina Tan ;

Katrina Croghan , MS;

Juliana Perez Botero , MD;

Briant Fruth ;

Deirdre Pachman , MD;

Veronica Lafky ;

Jeff Sloan , PhD;

Carrie Thompson , MD;

Rahma Warsame , MD;

Angela Dispenzieri , MD;

Abstract: Modern clinical practice places restrictions on the amount of information communicated in a typical office visit, impeding patient concerns from being adequately addressed. A point-of-care case management...

...

10/12/2016

Journal of Clinical Pathways

Research Reports

Associations Between Pre- and Post-Cancer Depression Diagnoses and End-of-Life Cancer Care Intensity

09/06/2016

Becca R. Levy , PhD;

Cary P. Gross , MD;

Kathy Doan , MPH;

Shi-Yi Wang , MD, PhD;

Abstract: Literature suggests that depression has adverse effects on health outcomes among patients with cancer. However, the associations between depression and end-of-life (EOL) cancer care are inconclusive. In...

...

09/06/2016

Journal of Clinical Pathways

Perspectives

In Defense of Meaningful Use: The Potential of Electronic Health Records Systems to Support Value-Based Care

08/02/2016

George S. Conklin ;

George A. Gellert , MD, MPH, MPA;

John A. Gillean , MD;

Lynn A. Gibson ;

S. Luke Webster , MD;

Abstract: The Meaningful Use Incentive Program from the Centers for Medicare & Medicaid Services (CMS) has successfully driven the adoption of electronic health records (EHRs). However, it has been criticized...

...

08/02/2016

Journal of Clinical Pathways

Perspectives

Frameworks for Assessing the Value of Cancer Drugs: Purely an Academic Exercise?

08/02/2016

Joshua P. Cohen , PhD;

Abstract: As the cost of prescription drugs increases, payers and providers alike have attempted to determine the value of treatments for high-cost disease, including cancer. In this article, the authors discuss the...

...

08/02/2016

Journal of Clinical Pathways

From the Field

A Method of Deriving Estimates of Health State Utilities for Patients With Metastatic Breast Cancer

06/20/2016

Gabriel Tremblay , DBA, MSc;

Stacie Hudgens , MA, MSc;

Andrew Briggs , DPhil, MSc;

Andrew J. Lloyd , DPhil;

Anna Forsythe , PharmD, MBA, MSc;

Abstract Patient-level health-related quality of life (HRQOL) for different stages of metastatic breast cancer (MBC) and chemotherapy regimen toxicities are useful for health economic assessments. However, it is...

...

06/20/2016

Journal of Clinical Pathways

Research Reports

SEASONS: A Prospective Study to Assess the Physical, Psychosocial, Spiritual, and Financial Needs of Breast and Prostate Cancer Survivors

06/20/2016

Brooke Hoverman ;

Stephanie Trenkner , BS;

Carlena Magley , BS;

Hilary Biddle , RN, BSN, CCRC;

Nancy Ehmke , RN, MN, AOCN;

Breck Hunnicutt , RN, BSN, CCRC;

Christina Zelt , RN, MSN;

Abstract: As cancer centers expand survivorship services beyond the delivery of the care plan to provide educational programs and support services, it is critical to assess survivors’ needs throughout their...

...

06/20/2016

Journal of Clinical Pathways

From the Field

Mock Clinical Pathways: A Method for Exploring the Oncology Clinical Pathway Development Process

05/06/2016

Bing-E Xu , PhD;

Bruce A. Feinberg , DO;

Monica Lingam , MS;

Abstract: Clinical pathways are a critical structural element in the effort to reduce variation in health care as well as to make costs and outcomes more predictable, measurable, and accountable. A mock clinical...

...

05/06/2016

Journal of Clinical Pathways

Research Reports

Cost-Effectiveness of Afatinib Versus Erlotinib in the First-line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With EGFR Exon 19 Deletion Mutations

05/06/2016

Rakesh Luthra , MS;

Jonathan Graham , BS;

Stephanie Earnshaw , PhD;

Rohit Borker , PhD;

Jonathan Lim , BS, MS, MSc;

Abstract: A decision model was developed to compare the cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth...

...

05/06/2016

Journal of Clinical Pathways

From the Field

Development and Implementation of De Novo Clinical Decision Support Rules at a Tertiary Cancer Center

04/11/2016

Aymen Elfiky , MD, MPH, MSc;

Marina Kaymakcalan , PharmD;

Abstract: The rising costs associated with cancer care delivery have prompted the health care system to prioritize the principle of value-based care to accentuate the concepts of quality and outcomes. Driven in...

...

04/11/2016

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Feature

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products